# Biodexa Pharmaceuticals Plc (BDRX)

Source page: https://stoqly.net/companies/bdrx

- **Ticker:** BDRX (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001643918
- **Latest annual report:** 20-F filed 2026-03-27 (https://www.sec.gov/Archives/edgar/data/1643918/000121465926003921/bp31726520f.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $3.43 on 2026-10-30
- **Revenue (FY2025):** $0.1M
- **Revenue growth:** −8.3%
- **Revenue growth, 5-year CAGR:** −24.9%
- **Operating margin:** −10,803.0%
- **Net margin:** −7,977.7%
- **Free cash flow:** −$7.4M
- **Free cash flow margin:** −6,989.2%
- **Return on invested capital:** −227.8%
- **Return on equity:** −65.2%
- **Net debt:** −$11.4M
- **Change in share count:** +1,007.7%
- **Piotroski F-score:** 4/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/bdrx/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 2 | 1 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Operating income | -13 | -17 | -16 | -14 | -30 | -10 | -11 | -10 | -12 | -11 |
| Net income | -27 | -21 | -20 | -13 | -28 | -8 | -9 | -9 | -7 | -8 |
| Diluted EPS (US$) | -75.60 | -39.92 | — | — | — | — | -1.91 | -0.02 | 0.00 | 0.00 |
| Operating cash flow | -18 | -17 | -18 | -8 | -12 | -8 | -9 | -8 | -16 | -7 |
| Free cash flow | -19 | -18 | -18 | -9 | -12 | -9 | -9 | -9 | -16 | -7 |
| Cash | 22 | 18 | 3 | 14 | 10 | 14 | 3 | 8 | 2 | 11 |
| Debt and leases | 2 | 8 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.